BioAtla, Inc. (BCAB) News & Overview - Discounting Cash Flows
BioAtla, Inc.
BCAB (NASDAQ)
Open 0.3946
Previous Close 0.3905
Volume 352.1 Thou.
Average Volume 515.8 Thou.
Day's Range 0.391 โ€“ 0.409
52 Week Range 0.24-2.525
Market Cap 23.23 Mil.
Moving Average (50) 0.43178
Moving Average (200) 0.89649
Earnings per Share (EPS) -1.22
Price/Earnings (PE) -0.33
Shares Outstanding 58.42 Mil.
Earnings Date Aug 06, 2025
Beta 0.911
Last Dividend 0

BCAB Latest News

BCAB Business Model

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

About BioAtla
Industry Biotechnology
Sector Healthcare
Number of Employees 61
Website & Executive
Website https://www.bioatla.com
CEO (Chief Executive Officer) Jay M. Short
IPO date 2020-12-16
Contact
Country US
Address 11085 Torreyana Road
City San Diego
State CA
Phone 858 558 0708
Zip Code 92121
Other Identifiers
CIK 0001826892
ISIN US09077B1044
CUSIP 09077B104
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us